Drug
Larotrectinib clinical trials
Also written LOXO-101, Vitrakvi and ARRY 470.
- studies test it
- 14
- open now
- 6
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the larotrectinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Studies by the year they started
13 studies that test it; most in 2015 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 12
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 11
National Cancer Institute (NCI) (4) · Bayer (3) · M.D. Anderson Cancer Center (2) · Children's Oncology Group (1) · Fujian Medical University (1) · Sun Yat-sen University (1) · West China Hospital (1) · Oslo University Hospital (1)
Often tested with
Tested in the same studies.
Crizotinib (3) · Dabrafenib (3) · Palbociclib (3) · Trametinib (3) · Pembrolizumab (3) · Pralsetinib (3) · Dasatinib (2) · Erdafitinib (2)
Studies
Open first, then newest update. How each study uses larotrectinib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid TumorsRecruitingPhase 2M.D. Anderson Cancer CenterNCT04879121Written as Larotrectinib Sulfate
- A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07843550Written as Larotrectinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Larotrectinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Larotrectinib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Larotrectinib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Larotrectinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Larotrectinib
- Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390852Written as Larotrectinib
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Larotrectinib Sulfate
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedPhase 2BayerNCT02576431Written as BAY2757556 (Larotrectinib, Vitrakvi)
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03213704Written as Larotrectinib Sulfate
- A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat CancerCompletedPhase 1BayerNCT02122913Written as Larotrectinib (Vitrakvi, BAY2757556)
- Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT03834961Written as Larotrectinib Sulfate
- A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenActive, not recruitingPhase 1/2BayerNCT02637687Written as Larotrectinib (Vitrakvi, BAY2757556)
Given in every arm · 1 — larotrectinib is usual care beside what is tested
Codes
What other systems call larotrectinib · ClinicalTrials.gg INT000494
- MeSH (NLM) C000609083larotrectinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) PF9462I9HXLAROTRECTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2105628Confirmed FDA, Wikidata
- Wikidata Q27081513larotrectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C115977LarotrectinibOne source FDA
- DrugBank DB14723One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609083 | larotrectinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | PF9462I9HX | LAROTRECTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2105628 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27081513 | larotrectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C115977 | Larotrectinib | One source FDA |
| DrugBank | DB14723 | — | One source Wikidata |
Also registered as larotrectinib sulfate (UNII RDF76R62ID · RxNorm 2104548).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.